Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Macquarie University, Australia
- Target Recruit Count
- 70
- Registration Number
- NCT06658977
- Locations
- 🇦🇺
Macquarie University, Neurology, North Ryde, New South Wales, Australia
🇦🇺Neuroscience Research Australia (NeuRA), Randwick, New South Wales, Australia
🇦🇺Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
STARLITE for Unresectable High-Grade Gliomas
- Conditions
- High Grade Glioma
- Interventions
- Procedure: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)Radiation: Focal Radiotherapy
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 24
- Registration Number
- NCT06428045
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
ABC Blocks for Cardiac Surgery
- Conditions
- Pain
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Duke University
- Target Recruit Count
- 50
- Registration Number
- NCT05589363
- Locations
- 🇺🇸
Duke University Hospital, Durham, North Carolina, United States
POC HIV Testing and Early DTG Use for Infants
- Conditions
- HIV
- Interventions
- Diagnostic Test: Point-of-Care Cepheid Xpert HIV-1
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Harvard School of Public Health (HSPH)
- Target Recruit Count
- 900
- Registration Number
- NCT05393193
- Locations
- 🇧🇼
Botswana Harvard HIV/AIDS Institute Partnership, Gaborone, Botswana
Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
- Conditions
- Aicardi-Goutières Syndrome
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 13
- Registration Number
- NCT04731103
- Locations
- 🇬🇧
Yanick Crow, Edinburgh, United Kingdom
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-06-27
- Target Recruit Count
- 57
- Registration Number
- NCT03760458
- Locations
- 🇧🇼
Gaborone CRS, Gaborone, Botswana
🇿🇦Famcru Crs, Tygerberg, Western Cape Province, South Africa
🇹🇭Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
- Conditions
- HIV-1-infectionSolid Organ Transplant
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 20
- Registration Number
- NCT03360682
- Locations
- 🇪🇸
Hospital Clínico y provincial de Barcelona, Barcelona, Spain
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
- Conditions
- Human Immunodeficiency Virus Infection
- Interventions
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Obafemi Awolowo University
- Target Recruit Count
- 194
- Registration Number
- NCT03284645
- Locations
- 🇳🇬
St. Thomas' Hospital, Ihugh, Benue State, Nigeria
🇳🇬Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria
🇳🇬St. Monica's Hospital, Adikpo, Benue State, Nigeria
Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide
- Conditions
- Renal Insufficiency,ChronicHivTherapeutic Agent Toxicity
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT02957864
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇳🇱OLVG, Amsterdam, Netherlands
🇳🇱Maasstad ziekenhuis, Rotterdam, Netherlands
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT02893488
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.